Multidisciplinary Respiratory Medicine, 2018 After publication of the Original research article [1] it was brought to our attention that the sentence at pag 6 (between Figure 3 and Figure 4)) must be corrected as follows: “The mean duration of inactivity was 2.88 (0.63) at baseline; 1.53 (0.27 ...
Roberto W. Dal Negro +2 more
doaj +1 more source
A view from the Bridge: agreement between the SF-6D utility algorithm and the Health utilities Index [PDF]
, 2003 BACKGROUND: The SF-6D is a new health state classification and utility scoring system based on 6 dimensions (‘6D’) of the Short Form 36, and permits a ‘‘bridging’’ transformation between SF-36 responses and utilities. The Health Utilities Index, mark 3
Brazier +14 more
core +1 more source
Фармакоэкономика, 2015 VII CONGRESS WITH INTERNATIONAL PARTICIPATION «DEVELOPMENT OF PHARMACOECONOMICS AND PHARMACOEPIDEMIOLOGY IN RUSSIAN FEDERATION»
doaj +2 more sources
Pharmacoeconomics of HIV-infection
Регуляторные исследования и экспертиза лекарственных средств, 2018 Ever since the first registrations of HIV-infections at the territory of the Russian Federation there was started a great process on arrangement and, subsequently, development of anti-HIV system.
R. I. Yagudina +3 more
doaj
PHARMACOECONOMIC ANALYSIS OF CHRONIC HEART FAILURE DRUG THERAPY IN PATIENTS WITH COMORBID CONDITIONS
Рациональная фармакотерапия в кардиологии, 2018 Aim. To perform pharmacoeconomic analysis of CHF therapy with supramolecular sacubitril/valsartan complex compared to routine therapy in patients with diabetes type 2 and ACE inhibitor intolerance within context of Russian healthcare system.Material and ...
S. K. Zyryanov +2 more
doaj +1 more source
Comparing the performance of the SF-6D and the EQ-5D in different patient groups [PDF]
, 2014 Introduction: This research aims to explore the performance of the SF-6D and the EQ-5D in patients suffering from asthma, chronic obstructive pulmonary disease, cataracts, and rheumatoid arthritis.
Ferreira, Lara N. +2 more
core +1 more source
PHARMACOECONOMIC ASPECTS OF EPLERENONE USAGE IN CHRONIC HEART FAILURE
Кардиоваскулярная терапия и профилактика, 2015 Eplerenone (Inspra, Pfizer) improves the prognosis of patients with chronic heart failure and heart failure after acute myocardial infarction. Since Russia eplerenone pharmacoeconomics issues rarely discussed, the analysis of the literature on this topic
Yu. M. Lopatin, E. Yu. Lopatina
doaj +1 more source
Incorporating economic evidence into cancer care: searching for the missing link [PDF]
Since the early 1980s it has been identified that even though economic evaluation is considered useful by economist it is not widely used by health care decision-makers. One of the ways to close the gap is to involve decision-makers in the process.
Gisselle Gallego +5 more
core
Cost-Utility Analysis of Venous Thromboembolism Prophylaxis Strategies for People Undergoing Elective Total Hip and Total Knee Replacement Surgeries in the English National Health Service [PDF]
, 2018 Background: Major orthopedic surgery, such as elective total hip replacement (eTHR) and elective total knee replacement (eTKR), are associated with a higher risk of venous thromboembolism (VTE) than other surgical procedures.
Anderson +53 more
core +4 more sources
A Claims-Based Algorithm for Identifying Hidradenitis Suppurativa Severity
Clinical EpidemiologyMaria C Schneeweiss,1– 3 Priyanka Anand,1,2 Arash Mostaghimi,2,3 Joan Landon,1,2 Denys Shay,1,4 Olivia MT Davies,2,3 Anusha Mohan Kumar,2,3 Aijing Shang,5 Tanja Tran,6 Robert J Glynn,1,2 Kueiyu Joshua Lin,1,2,7,8 Richard Wyss1,2 1Division of ...
Schneeweiss MC +11 more
doaj